Integrating women's well-being, global expansion and social contribution under the 2030 Vision

「To realize Long-Term Vision 2035, the company’s 4 growth strategies through the fiscal year ending September 2029 are "expanding our contribution to women’s healthcare," "expanding our contribution through the biosimilar business," "contributing earnings through the global CMO business," and "developing and assessing the next growth drivers."」

「Fuji Pharmaceutical Co., Ltd. Group has formulated Long-Term Vision 2035 as its vision of continuing to create value into the future by further cycling the cycle of growth and contribution, its management philosophy. To realize Long-Term Vision 2035, over the next 5 years it is pursuing the following 4 growth strategies as its medium-term management plan: expanding its contribution to women's healthcare; expanding its contribution through the biosimilars business; generating earnings contributions through the global CMO business; and preparing for and identifying the next growth drivers. These are supported by 3 initiatives to strengthen the management foundation: strengthening human resources; upgrading organizational capabilities; and promoting digitalization.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group has formulated a medium-term management plan with the fiscal year ending September 2024 as its final fiscal year.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group has formulated a medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group has formulated a medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group has formulated a medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision. Under the plan, themed "Renewing what it means to be Fuji," the group is pursuing a growth strategy toward 2030 by strengthening its women's healthcare and acute-care healthcare businesses, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars and generic drugs so that it can expand further over the subsequent 5 years.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group formulated a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group formulated a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group formulated a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group formulated a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group formulated a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group formulated a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group formulated a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision.」

「Under its 2030 Vision, the group has identified its desired state 10 years from now as contributing to improved well-being for women worldwide, expanding into global markets from Toyama, the home of medicines, and integrating the world's happiest company with social contribution. To achieve this, the group formulated a new medium-term management plan as a roadmap toward the fiscal year ending September 2024, an interim milestone on the way to that vision.」

「To steadily implement these initiatives and put its management philosophy into practice, the company formulated and announced the 2030 Vision, defining its desired state as of the end of the fiscal year ending September 2029.」

「Under these circumstances, the Group has newly adopted the following as its 2030 vision: “Contributing to improving the well-being of women worldwide,” “Expanding from Toyama, the home of pharmaceuticals, into the Global Market,” and “Integrating the world’s happiest company with contributions to society.” The entire Group is working on its growth strategy toward 2030.」

「Under these circumstances, the Group has newly adopted the following as its 2030 vision: “Contributing to improving the well-being of women worldwide,” “Expanding from Toyama, the home of pharmaceuticals, into the Global Market,” and “Integrating the world’s happiest company with contributions to society.” The entire Group is working on its growth strategy toward 2030.」

「Under these circumstances, the Group has newly adopted the following as its 2030 vision: “Contributing to the well-being of women worldwide,” “Expanding from Toyama, the home of pharmaceuticals, into the Global Market,” and “Integrating the world’s happiest company with contributions to society.” The entire Group is working on its growth strategy toward 2030.」